These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 10802692)

  • 1. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.
    Restifo NP
    Nat Med; 2000 May; 6(5):493-5. PubMed ID: 10802692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fas, fas ligand, immune tolerance, and cancer: implications in cancer of the colon].
    Berger A; Piqueras B; Pages F; Tartour E; Cugnenc PH; Fridman WH
    Bull Cancer; 1998 Feb; 85(2):129-33. PubMed ID: 9752329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of Fas ligand in immune privilege.
    Green DR; Ferguson TA
    Nat Rev Mol Cell Biol; 2001 Dec; 2(12):917-24. PubMed ID: 11733771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
    Greil R; Egle A; Villunger A
    Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
    Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
    Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape.
    Huber V; Fais S; Iero M; Lugini L; Canese P; Squarcina P; Zaccheddu A; Colone M; Arancia G; Gentile M; Seregni E; Valenti R; Ballabio G; Belli F; Leo E; Parmiani G; Rivoltini L
    Gastroenterology; 2005 Jun; 128(7):1796-804. PubMed ID: 15940614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack.
    Maher S; Toomey D; Condron C; Bouchier-Hayes D
    Immunol Cell Biol; 2002 Apr; 80(2):131-7. PubMed ID: 11940113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A vision of cell death: insights into immune privilege.
    Ferguson TA; Griffith TS
    Immunol Rev; 1997 Apr; 156():167-84. PubMed ID: 9176707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune privilege or inflammation? The paradoxical effects of Fas ligand.
    O'Connell J
    Arch Immunol Ther Exp (Warsz); 2000; 48(2):73-9. PubMed ID: 10807046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unraveling immune privilege.
    Streilein JW
    Science; 1995 Nov; 270(5239):1158-9. PubMed ID: 7502038
    [No Abstract]   [Full Text] [Related]  

  • 11. Cell death and immune privilege.
    Ferguson TA; Green DR; Griffith TS
    Int Rev Immunol; 2002; 21(2-3):153-72. PubMed ID: 12424841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications.
    Strand S; Galle PR
    Mol Med Today; 1998 Feb; 4(2):63-8. PubMed ID: 9547792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Fas ligand in conferring immune privilege to non-lymphoid cells.
    Guller S
    Ann N Y Acad Sci; 1997 Sep; 828():268-72. PubMed ID: 9329847
    [No Abstract]   [Full Text] [Related]  

  • 14. The Fas/Fas ligand system and cancer: immune privilege and apoptosis.
    Abrahams VM; Kamsteeg M; Mor G
    Mol Biotechnol; 2003 Sep; 25(1):19-30. PubMed ID: 13679631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Die and let live: eliminating dangerous lymphocytes.
    Abbas AK
    Cell; 1996 Mar; 84(5):655-7. PubMed ID: 8625402
    [No Abstract]   [Full Text] [Related]  

  • 16. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction.
    Kang SM; Schneider DB; Lin Z; Hanahan D; Dichek DA; Stock PG; Baekkeskov S
    Nat Med; 1997 Jul; 3(7):738-43. PubMed ID: 9212099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fas-ligand: privilege and peril.
    Green DR; Ware CF
    Proc Natl Acad Sci U S A; 1997 Jun; 94(12):5986-90. PubMed ID: 9177153
    [No Abstract]   [Full Text] [Related]  

  • 18. Tumor escape mechanism involving Fas and Fas-L molecules in human colorectal tumors.
    Radfar S; Martin H; Tilkin-Mariame AF
    Gastroenterol Clin Biol; 2000 Dec; 24(12):1191-6. PubMed ID: 11173732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell death and the immune response: a lesson from the privileged.
    Ferguson TA; Griffith TS
    J Clin Immunol; 1997 Jan; 17(1):1-10. PubMed ID: 9049780
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of antibody signaling in inducing tumor dormancy.
    Uhr JW; Marches R; Racila E; Tucker TF; Hsueh R; Street NE; Vitetta ES; Scheuermann RH
    Adv Exp Med Biol; 1996; 406():69-74. PubMed ID: 8910672
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.